Item 7.01 Regulation FD Disclosure.

On January 25, 2023, Mersana Therapeutics, Inc. (the "Company") posted an updated corporate presentation on the Company's website. To access the presentation, investors should visit the "Events & Presentations" page under the "Investors & Media" section of the Company's website at ir.mersana.com.

The information furnished under this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company with the Securities and Exchange Commission under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.




 Item 8.01 Other Events.

On January 25, 2023, the Company issued a press release announcing the initiation of patient dosing in its Phase 1 clinical trial of XMT-2056, the Company's lead Immunosynthen product candidate. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits



Exhibit No.   Description
  99.1          Press Release issued by the Company on January 25, 2023.
              Cover Page Interactive Data File (embedded within the Inline XBRL
104           document).

© Edgar Online, source Glimpses